Relmada Therapeutics Inc. RLMD
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies for central nervous system disorders and oncology indications. Its primary efforts center on NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel designed for the treatment of non-muscl…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees17
TickerRLMD
Statistics
Market Cap$693.8M
Revenue (TTM)—
Net Income-$57.4M
Net Margin—
EPS$-1.45
P/E-4.58
P/S—
P/B5.64
EV/EBITDA2.93
ROE-25.6%
Dividend Yield—
Price$6.62
Data: Twelve Data · Revenue = mcap / P/S